Skip to content
Lucentis(ranibizumab)
Byooviz, Cimerli, Lucentis, Susvimo (ranibizumab) is an antibody pharmaceutical. Ranibizumab was first approved as Lucentis on 2006-06-30. It is used to treat diabetic retinopathy, macular edema, and retinal vein occlusion in the USA. It has been approved in Europe to treat degenerative myopia, diabetes complications, diabetic retinopathy, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A. In addition, it is known to target Vascular endothelial growth factor A.
Download report
Favorite
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Byooviz, Cimerli, Lucentis, Susvimo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ranibizumab
Tradename
Proper name
Company
Number
Date
Products
LucentisranibizumabGenentechN-125156 RX2006-06-30
4 products
SusvimoranibizumabGenentechN-761197 RX2021-10-22
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
byooviz Biologic Licensing Application2022-04-27
cimerliBiologic Licensing Application2022-09-22
lucentisBiologic Licensing Application2020-10-20
susvimoBiologic Licensing Application2021-03-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic retinopathyEFO_0003770D003930
macular edemaD008269
retinal vein occlusionEFO_1001157D012170H34.81
Agency Specific
FDA
EMA
Expiration
Code
ranibizumab, Cimerli, Coherus BioSciences, Inc.
Date TBDInterchangeable excl.
Patent Expiration
No data
ATC Codes
S: Sensory organ drugs
S01: Ophthalmologicals
S01L: Ocular vascular disorder agents
S01LA: Antineovascularisation agents
S01LA04: Ranibizumab
HCPCS
Code
Description
J2778
Injection, ranibizumab, 0.1 mg
Clinical
Clinical Trials
524 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.302871623731205
Macular edemaD0082691747322424128
Retinal vein occlusionD012170EFO_1001157H34.81101018141056
Choroidal neovascularizationD02025651596133
Diabetic retinopathyD003930EFO_000377021278229
Wet macular degenerationD057135EFO_0004683534112
Retinal neovascularizationD015861H35.053532112
Vision disordersD014786HP_0000505H53.114318
Retinal diseasesD012164HP_0000479H35.932127
Neovascular glaucomaD015355EFO_1001060122217
Show 14 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Retinopathy of prematurityD012178EFO_1001158H35.11359
GlaucomaD005901EFO_0000516H4023226
UveitisD014605EFO_1001231H20.92214
PterygiumD011625H11.02113
Degenerative myopiaD047728H44.22113
Diabetes complicationsD0489091112
Retinal hemorrhageD012166HP_0000573H35.61112
Diffuse cerebral sclerosis of schilderD002549Orphanet_726G31.81111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TelangiectasisD013684415
Von hippel-lindau diseaseD006623Q85.83323
Retinal degenerationD012162HP_0001105212
Retinal telangiectasisD058456Orphanet_190H35.021112
IschemiaD007511EFO_0000556212
Retinal dystrophiesD058499Orphanet_7186211
Diabetic angiopathiesD003925EFO_1000896111
Cardiovascular diseasesD002318EFO_0000319I98111
Retinal perforationsD012167EFO_100102811
RetinoblastomaD01217511
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Corneal neovascularizationD016510EFO_1000880H16.422
Hereditary hemorrhagic telangiectasiaD013683I78.011
EpistaxisD004844EFO_0003895R04.011
DepressionD003863F33.911
Port-wine stainD019339Q82.511
Neurofibromatosis 1D009456Q85.0111
NeurofibromaD009455EFO_000062211
Open-angle glaucomaD005902EFO_0004190H40.111
BlisterD00176811
Ischemic optic neuropathyD018917EFO_1000809H47.0111
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intraocular pressureD00742911
Regional blood flowD01203911
Cataract extractionD00238711
Premature infant diseasesD00723511
Geographic atrophyD05709211
Researcher-subject relationsD03584411
Epiretinal membraneD019773HP_010001411
Sickle cell anemiaD000755EFO_0000697D5711
Retinal arterial macroaneurysmD00008034611
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRANIBIZUMAB
INNranibizumab
Description
Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 gamma1-chain), disulfide with human-mouse monoclonal rhuFAB V2 kappa-chain
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)RANIBIZUMAB
Structure (InChI/SMILES or Protein Sequence)
>1CZ8:H,Y|HEAVY CHAIN OF NEUTRALIZING ANTIBODY EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY LQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL >1CZ8:L,X|LIGHT CHAIN OF NEUTRALIZING ANTIBODY DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB1CZ8
CAS-ID347396-82-1
RxCUI595060
ChEMBL IDCHEMBL1201825
ChEBI ID
PubChem CID
DrugBankDB01270
UNII IDZL1R02VT79 (ChemIDplus, GSRS)
Target
Agency Approved
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
Protein name
vascular endothelial growth factor A
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A (Q00731)
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
Mouse ortholog
Variants
Clinical Variant
No data
Financial
Cimerli - Coherus BioSciences
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Byooviz - Biogen
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Lucentis - Novartis
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Lucentis - Roche
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 11,229 documents
View more details
Safety
Black-box Warning
Black-box warning for: Susvimo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,731 adverse events reported
View more details